Alleh Lindquist

CEO of FloraWorks, Alleh Lindquist, is revolutionizing cannabinoid research and development. Using advanced oxidative chemistry, FloraWorks synthesizes diverse cannabinoids, including novel ones, targeting optimal therapeutic efficacy. Their recent focus? CBN for sleep disturbance. Validated by a blinded, placebo-controlled study, they're pushing for mainstream CBN adoption. Concurrently, in collaboration with the Salk Institute, they're honing in on dementia-related treatments, with pivotal data from innovative experiments underway. Lindquist ensures FloraWorks stays at the cutting edge, continually expanding research horizons.